Skip to main content

Table 2 Baseline clinical characteristics of the patients with RIF in the experimental and control groups

From: The role of transcriptomic biomarkers of endometrial receptivity in personalized embryo transfer for patients with repeated implantation failure

Characteristic Experimental (n = 56) Control (n = 86) P-value
No. of previous failed cycles, median (IQR) 3 (2–4) 3 (3–4) 0.462
Age, mean ± SD, y 32.71 ± 4.14 32.90 ± 3.79 0.789
BMI, mean ± SD, kg/m2 21.38 ± 2.39 21.41 ± 1.85 0.926
Infertility duration, mean ± SD, y 5.18 ± 3.42 4.38 ± 3.29 0.168
AMH, median (IQR), ng/ml 2.86 (1.40–5.33) 4.10 (2.31–6.15) 0.154
FSH, mean ± SD, mIU/ml 6.49 ± 1.59 6.27 ± 1.67 0.478
AFC, mean ± SD 12.55 ± 6.91 13.92 ± 6.50 0.261
Endometrial thickness, mean ± SD, mm 9.47 ± 1.85 9.26 ± 1.42 0.469
P levels on the day of progesterone administration/LH peak, median (IQR), ng/ml 0.31 (0.09–0.61) 0.29 (0.15–0.72) 0.529
Types of infertility
 Primary infertility (n/%) 33 (58.9%) 41 (47.7%) 0.190
 Secondary infertility (n/%) 23 (41.1%) 45 (52.3%)
IVF indication
 Male factor (n/%) 2 (3.6%) 3 (3.5%) 0.704
 Tubal factor (n/%) 50 (89.3%) 82 (95.3%)
 PCOS (n/%) 6 (10.7%) 11 (12.8%)
 Diminished ovarian reserve (n/%) 6 (10.7%) 9 (10.5%)
 Endometriosis (n/%) 5 (8.9%) 3 (3.5%)
 Others (n/%) 2 (3.6%) 1 (1.2%)
Sampling cycle protocol
 Natural cycle (n/%) 26 (46.4%) 34 (39.5%) 0.416
 HRT cycle (n/%) 30 (53.6%) 52 (60.5%)
No. of transferred embryos, median (IQR) 2 (2–2) 2 (2–2) 0.608
Total no. of transferred embryos (n) 90 158  
Embryo stage
 D3 cleavage-stage embryos (n/%) 51 (56.7%) 114 (72.2%) 0.013
 D5 or D6 blastocysts (n/%) 39 (43.3%) 44 (27.8%)
  1. Bold value indicates statistical significance
  2. BMI body mass index, AMH anti-Mullerian hormone, FSH follicle-stimulating hormone, AFC antral follicle count, P levels serum endogenous progesterone level, PCOS polycystic ovarian syndrome, HRT cycle hormone replacement cycle